Literature DB >> 12096226

Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study.

N J Cooper1, M Mugford, D P M Symmons, E M Barrett, D G I Scott.   

Abstract

OBJECTIVE: To estimate the health service, non-health service and total costs and predictors of costs in individuals with early inflammatory polyarthritis (IP).
METHODS: We conducted a prospective longitudinal study over a 6-month period. The participants were a random sample of 133 individuals who had enrolled with the community-based Norfolk Arthritis Register (NOAR) database between 1994 and 1999. The main outcome measures were the mean (per person) 6-month health service cost, non-health-service cost and total cost associated with IP.
RESULTS: One hundred and fifteen of the 133 individuals who were recruited into the study completed 6 months of follow-up. The mean 6-month total cost was estimated to be 2800 pounds sterling per person, of which 14% was health service costs and the remainder non-health-service costs. Higher total costs were associated with lower health status and rheumatoid factor positivity.
CONCLUSIONS: Early IP has a considerable impact on both the health-care system and, more importantly, society. Non-health-service costs (i.e. costs incurred by the individual with the disease, their family and friends) account for a substantial proportion (86%) of the total costs associated with early IP.

Entities:  

Mesh:

Year:  2002        PMID: 12096226     DOI: 10.1093/rheumatology/41.7.767

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  9 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Randomised controlled trial and cost consequences study comparing initial physiotherapy assessment and management with routine practice for selected patients in an accident and emergency department of an acute hospital.

Authors:  B Richardson; L Shepstone; F Poland; M Mugford; B Finlayson; N Clemence
Journal:  Emerg Med J       Date:  2005-02       Impact factor: 2.740

3.  Direct costs related to rheumatoid arthritis: the patient perspective.

Authors:  J L Hülsemann; T Mittendorf; S Merkesdal; S Handelmann; J-M von der Schulenburg; H Zeidler; J Ruof
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

4.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Burden and cost of illness in patients with juvenile idiopathic arthritis.

Authors:  K Minden; M Niewerth; J Listing; T Biedermann; M Schöntube; A Zink
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

6.  Cost of illness for patients with arthritis receiving multidisciplinary rehabilitation care.

Authors:  Margreth Grotle; Kåre Birger Hagen; Till Uhlig; Eline Aas
Journal:  Rehabil Res Pract       Date:  2011-07-26

7.  Factors associated with costs and health outcomes in patients with Back and leg pain in primary care: a prospective cohort analysis.

Authors:  Jesse Kigozi; Kika Konstantinou; Reuben Ogollah; Kate Dunn; Lewis Martyn; Susan Jowett
Journal:  BMC Health Serv Res       Date:  2019-06-21       Impact factor: 2.655

Review 8.  Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?

Authors:  Kei Ikeda; Sally Cox; Paul Emery
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

9.  The outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis: a non-randomised pragmatic study.

Authors:  Richard A Watts; Janice Mooney; Garry Barton; Alex J MacGregor; Lee Shepstone; Lisa Irvine; David G I Scott
Journal:  BMJ Open       Date:  2015-08-25       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.